Daily Dose - Jan 6th, 2026
Daily Dose |
View online
January 6, 2026
The next phase of radioligand therapies is about execution
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Read More
ProBioGen, Zag Bio ink CMC partnership to support autoimmune therapy
The agreement covers cell line development, process development, and GMP manufacturing for a lead Fc-fusion candidate targeting Type 1 diabetes.
Read More
Title21 Health Solutions acquires MyCellHub and its manufacturing execution system
The acquisition adds to Title21’s digital capabilities for healthcare and life sciences organizations across the cell and gene therapy ecosystem.
Read More